Paroxysmal Nocturnal Hemoglobinuria PNH Jamile M Shammo, MD, FASCP, FACP Associate Professor of Medicine and Pathology Rush University Medical Center Chicago 1 Outline • How frequent is PNH? • How does it happen? • What are the symptoms and risks? • How is it diagnosed? • How is it treated? 2 PNH : Epidemiology • An estimated 4,000 – 6,000 patients in U.S.1 • Median age of diagnosis is early 30’s2,3,4 • 5 year mortality: 35%2 1Hill, et al. Blood. 2006;108:972. et al. Br J Haematol. 2004;126:133-138. 3Socie, et al. Lancet. 1996;348:573-577. 4Nishimura, et al. Medicine. 2004;83:193–207. 2Moyo, 3 Paroxysmal Nocturnal Hemoglobinuria: Actuarial Survival From the Time of Diagnosis in 80 Patients With PNH1 Patients Surviving (%) 100 80 Age- and sexmatched controls 60 40 Patients with PNH 20 0 0 5 10 15 20 25 Years After Diagnosis The expected survival of an age- and sex-matched control group is shown for comparison (Hillmen et al 1995). In a patient population where ½ the patients have <30% clone, 1 in 7 patients died by 5 years (de Latour et al. Blood. 2008; 112: 3099-3106) 1. Hill A et al. Blood. 2006;108(11): 290a. Abstract 985 2. Hillmen, et al. N Engl J Med. 1995;333:1253-1258. 3. Nishimura JI, et al. Medicine. 2004;83:193-207. 4. Socié G et al. Lancet. 1996;348:573-77. 5. Hill A et al. Br J Haematol. 2007;137:181-92. 44 Paroxysmal Nocturnal Hemoglobinuria How does it happen? • This is an acquired mutation of a gene (PIG-A) on the X chromosome important in making protein anchors (GPI). • GPI protein anchors on the surface of all blood cells • • protecting the red cells from destruction by a component of the immune system known as complement. When the anchor and it’s associated proteins are missing, red cells become susceptible to destruction by the complement system. Complement system is designed to attack bacteria, it kills them by poking holes in the membrane-what is called the Membrane Attack Complex (MAC) 5 PNH • PNH red cells are deficient in all GPI anchored protein, but 2 are important in protecting red cells from destruction: CD55 (DAF) and CD59 (MIRL). • Without these proteins, red cells don’t have their normal protection against the complement system. • In PNH, there is uncontrolled, complement mediated hemolysis (destruction of red cells). • This happens all the time, and is accelerated when there is an event that activates the complement system. 6 The Defect in PNH GPI-anchor & membrane proteins PROTEIN Asp NORMAL C=O NH CH 2 CH 2 O PNH O=P=O O ( 1-2) ( 1-6) ( 1-4) O N O-P=O O CH CH NH 2 2 2 O O-P-O CH O 2 CH O CH O 2 C=O C=O 77 The Complement System Microorganisms Terminal Proximal Lectin Antigen-Antibody Classical C3 Constitutive/ Microorganisms Alternative C3a Microbial opsonization Immune complex clearance C3b C5 C5b Weak anaphylatoxin C5a C5b-9 Figueroa JE, et al. Clin Microbiol Rev. 1991;4:359-395. Walport. N Engl J Med. 2001;344:1058-66. Strong anaphylatoxin Terminal Complement Complex (TCC) Cause of Hemolysis in PNH Lysis of Neisseria 8 Absence of CD59 Allows Terminal Complement Complex Formation C9 CD55 C5b-8 CD59 C5b-8 CD59 C9 C9 Walport MJ, et al. N Engl J Med 2001;344:1058-1066 +9 PNH is a Progressive Disease of Chronic Hemolysis Normal red blood cells Without this protective are protected from complement attack by a shield of terminal complement inhibitors complement inhibitor shield, PNH red blood cells are destroyed Thrombosis Renal Failure Significant Impact on Survival Pulmonary Hypertension Abdominal Pain Complement Activation Dyspnea Dysphagia Intact RBC Fatigue Significant Impact on Morbidity Free Hemoglobin Hemoglobinuria Anemia Erectile Dysfunction International PNH Interest Group. Blood. 2005;106:3699-3709; Brodsky R. Paroxysmal Nocturnal Hemoglobinuria. In: Hematology - Basic Principles and Practices. 4th ed. R Hoffman; EJ Benz; S Shattil et al, eds. Philadelphia, PA: Elsevier Churchill Livingstone; 2005; p. 419-427; Rother RP et al. JAMA. 2005;293:1653-1662; Socie G et al. Lancet. 1996;348:573-577; Hill A et al. Br J Haematol. 2007;137:181-92. 10 10 Paroxysmal Nocturnal Hemoglobinuria • • • It’s not just paroxysmal – Even in the absence of symptoms, destructive progression of hemolysis is ongoing It’s not always nocturnal – Hemolysis in PNH is subtle and constant, 24 hours a day Hemoglobinuria is the hallmark of this disease, however: – ¾ patients present without hemoglobinuria1 1. International PNH Interest Group. Blood. 2005;106:3699-3709. 11 PNH Symptoms Clinical signs or symptoms Thrombosis Anemia Bone marrow failure Fatigue, impaired QOL Hemoglobinuria Abdominal Pain Dysphagia Erectile Dysfunction Chronic Renal Insufficiency (GFR<60/ml/min) Incidence Rate (%) 40%1 89%7 10-45%2-5 96%6 26%7 57%6 41%6 47%6 30%8 Average delay to diagnosis > 3 years; may be > 10 years1 1. Hillmen, et al. N Engl J Med. 1995;333:1253-1258. 2. Johnson & Hillmen. J Clin Path: Mol Pathol. 2002;55:145-152. 3. Wang, et al. Blood. 2002;100:3897-3902. 4. Iwanga, et al. Brit J Haem. 1998;102:465-474. 5. Maciejewski, et al. Brit J Haem. 2001;115:1015-1022. 6. Meyers G et al. Abstract submitted to ASH 2007 for fatigue. 7. Rosse. Paroxysmal nocturnal hemoglobinuria In: R Hoffman; EJ Benz; SJ Shattil et al., eds. Hematology: Basic Principles and Practice. 3rd ed. New York: Churchill-Livingstone; 2000:331-342. 8. Clark DA, et al. Blood. 1981;57:83-89. 12 Impact of PNH on Quality of Life ~75% of Patients Reported Symptoms as Moderate to Severe 59% patients were transfusion-free for at least 12 mo or had never been transfused 76% were forced to modify their daily activities to manage their PNH 17% were unemployed due to PNH *Moderate to severe; N=29. Meyers G et al. Blood. 2007;110 (11): Abstract 3683. 13 13 Abdominal Pain and Ischemia in • Abdominal pain is associated with hemolysis1 PNH • Hemolysis causes nitric oxide consumption • leading to vasoconstriction, smooth muscle contraction, and ischemia1,2 Severe abdominal pain observed with intestinal ischemia:3,4 – Marked elevation of d-dimers5,6 – Electron microscopic findings of ischemia on biopsy3 – Venous blockage by angiography or MRI6 1. Hill A et al. Haematologica. 2005;90(e-case)40. 2. Rother R et al. JAMA.2005;293:1653-62. 3. Adams T et al. Digestive Diseases and Sciences. 2002; 47(1):58–64. 4. Quentin V et al. Gastroenterol Clin Biol. 2003;27(10):927-31. 5. Weitz I et al. Blood. 2008; 112: Abstract 407. 6. Khoshini R et al. Med Gen Med. 2004; 6(1): 23. 14 14 Common Symptoms of Hemolysis Signal the Underlying Threat of Catastrophic Consequences Dyspnea Dysphagia Abdominal Pain Impaired QoL Fatigue Hemoglobinuria Erectile Dysfunction Anemia DVT Acute Renal Failure Chronic Kidney Disease Stroke / TIA Hepatic Failure Cardiac Dysfunction Ischemic Bowel Pulmonary Hypertension 15 15 Thrombosis in PNH: • 40% of patients with clinical thrombotic events1 • Leading cause of death2 – Accounts for 40–67% of deaths1 – First thrombotic event can be fatal2 – Median time to TE was 2.1-2.3 years from diagnosis3 – First TE increases risk for death 5 to 10-fold1 • Risk of thrombosis with smaller clone size4 – 4-fold increase in thrombotic risk for every 10% increase in clone size2 1. Hillmen et al. Blood 2007; 110: 4123-4128. 2. International PNH Group et al. Blood. 2005;106(12):3699-3709. 3. De Latour. Blood 2008 p. 3102 4. Audebert HJ et al. J Neurol. 2005;252:1379-1386. 16 16 Common Sites of Thrombosis Occur Frequently in PNH Hillmen P et al. 1995 (N=80) Hillmen P et al. 2007 (N=195) DVT or PE 33% 40% CVA/MI 16% 15% Typical VTE most common VTE in PNH √ √ Atypical VTE more common in PNH than in the general population3 √ √ TE Type Higher proportion of PE and/or DVT sites of thrombosis consistently found in PNH patients – Socie et al. 1996 (29%)4 and Nishimura and Rosse. 2004 (27%)5 1. Hillmen P et al. N Engl J Med. 1995;333:1253-8. 2. Hillmen P et al. 12. Blood. 2007; 100:4123-8. 3. Fowkes FJI et al. Eur J Vasc Endovasc Surg. 2003;25:1-5. 4. Socie G et al. Lancet. 1996;348:573-7. 5. Nishimura J et al. Medicine. 2004;83(3):193-207. 17 17 Thrombosis Event Rate (TE Per 100 Pt-Yrs) Elevated Thrombotic Rate in Antithrombotic-Treated Patients 12 10.61 10 8 6 4 2 (n=103) 0 Antithrombotic-Treated Patients 91 Were Receiving Anticoagulants Hillmen et al. Blood. 2007;110:4123-4128. 18 18 Thrombosis Fatigue / Impaired QOL Pulmonary Hypertension End Organ Damage Anemia Renal Damage in PNH • Renal failure has been identified as the cause of death in approximately 8 – 18% of PNH patients1 • Renal function impaired in PNH patients2 – 13/19 (68%) with significant reduction in creatinine clearance – 6/19 (32%) GFR <60 1.Nishimura JI, et al. Medicine. 2004;83:193-207. 2. Clark DA et al. Blood. 1981 Jan;57(1):83-9; 19 19 64% of Patients Exhibit Clinical Chronic Kidney Disease (CKD) 59% of patients with minimal (0-1) transfusion history had CKD (n=22) Hillmen et al. Blood. 2007; 110 (11): Abstract 3678. 20 20 PNH and Pulmonary Hypertension • Hemolysis results in cell-free hemoglobin • • • and Nitric oxide (NO) consumption leading to pulmonary hypertension1, 2 47% of PNH patients have pulmonary hypertension3 PNH patients with pulmonary hypertension have cardiac dysfunction3 66% of PNH patients report dyspnea4 1. Rother R. et al. JAMA. 2005; 293: 1653-1662. 2. Hill A et al. BJH. 2010:1-12; 3. Hill A et al. Br J Haematol. 2006;133 (suppl 1):119:Abstract 316. 4. Meyers G et al. Blood. 2007;110(11):Abstract 3683; 21 21 Who Should be Tested for PNH? • Patients with unexplained hemolytic anemia • Patients with bone marrow failure, including aplastic anemia and MDS • Patients with hemoglobinuria • Patients with unusual/repetitive thrombosis, and arterial thrombosis otherwise unexplained. • Patients with episodic swallowing problems or abdominal pain of unclear etiology with associated hemolysis 22 23 How is PNH diagnosed? • physicians need to consider the disease as a potential diagnosis when evaluating their patients and eventually request the diagnostic test. • Flow cytometry, typically performed on peripheral blood, allows for the detection of cells deficient in the GPI anchor and it’s associated proteins . It estimates: – 1. The size of the PNH clone – 2. The extent of deficiency of membrane proteins (Type II, partial, and type III complete deficiency of CD55 and CD59) • Flow tests should be followed periodically monitor the size of the clone. It is important that flow tests be performed on both red and white cells. • 24 Diagnosis of PNH in Red Blood Cells Normal RBC’s with normal CD59 expression (Type I cells) PNH clone with complete CD59 deficiency (Type III cells) Gating on GPA+ RBC’s PNH clone with complete CD59 deficiency (Type III cells) and partial CD59 deficiency (Type II cells) 25 Why look beyond RBCs for PNH? • Percentages of PNH RBCs may be affected • • by: • Hemolysis • Blood Transfusion Granulocyte clone size provides true PNH clone size PNH reports should provide quantitative results expressing clone size on both granulocytes and erythrocytes1 1. Hall & Rosse. Blood. 1996;87:5332-5340. 26 White Cell Staining with anti-CD59 From Hall SE and Rosse WF, Blood 1996; 87: 5332 27 PNH Patient with an 80% WBC clone size and 31% RBC clone size indicating Hemolysis 28 Evidence of PNH Cells in Aplastic Anemia EXPLORE Trial Percent Positive: WBC PNH cells/clone > 0.01% • AA (N = 451)1 69.6% (314 / 451) Percent Positive : WBC PNH clone ≥ 1% 25.1% (113 / 451) Median Clone Size: WBC PNH clone ≥ 1% 7.4% (n=113) Mean Clone Size: WBC PNH clone ≥ 1% 24.1% (n=113) % of patients with clone ≥1% and LDH > ULN 38.1% (n=113) Interim Results from EXPLORE, a Multi-center Prevalence Study of PNH Clone Size in Patients with AA, MDS, and other BMF 1. Galili N et al. Poster presentation at: American Society of Clinical Oncology 45th Annual Meeting; May 29–June 2, 2009; Orlando, FL.. 29 Evidence of PNH Cells in MDS • • EXPLORE Trial MDS (N = 4433)1 Percent Positive: WBC PNH cells/clone > 0.01% 55.2% (2447 / 4433) Percent Positive : WBC PNH clone ≥ 1% 1.2% (54 / 4433) Median Clone Size: WBC PNH clone ≥ 1% 13.3% (n=54) Mean Clone Size: WBC PNH clone ≥ 1% 33.7% (n=54) % of patients with clone ≥1% and LDH > ULN 44.4% (n=54) Interim Results from EXPLORE, a Multi-center Prevalence Study of PNH Clone Size in Patients with AA, MDS, and other BMF PNH cells were identified in 55% of all MDS patients. Similar proportions of PNH cells were identified in all MDS subtypes including RA, RCMD, RARS, RAEB, RCMD-RS and 5 q syndrome. 1. Galili N et al. Poster presentation at: American Society of Clinical Oncology 45th Annual Meeting; May 29–June 2, 2009; Orlando, FL.. 30 Immunosuppressive Therapy With ATG/CSA in MDS Patients Recommendations based on: • PNH positive cells may reflect BM-directed T-cell activity in MDS1 Hematologic Improvement PNH+ 78% (n=9) PNH0% (n=8; P=0.002) 89% (n=9) 27% (n=30; P=0.0015) 1. Dunn DE et al. Ann Intern Med. 1999;131:401-8. 2. Wang H et al. Blood. 2002;100(12):3897-902. MDS Type/ Rx RA w/CSA2 MDS w/ATG1 31 Management of PNH • Transfusions • • • • • – Risk of iron overload – Transient treatment of anemia Anticoagulants – Risk of hemorrhage – Ineffective in many patients* Red cell supplements – Folic acid, iron, – erythropoiesis-stimulating agents Steroids/androgen hormones Bone marrow transplant Eculizumab (Soliris) ESA=erythropoietin stimulating agents International PNH Interest Group. Blood. 2005;106:3699-3709. *Hillmen P et al. Blood. 2007;110:4123-8. 32 32 Bone Marrow Transplant BMT is associated with significant morbidity and mortality, and a significant impact on quality of life post transplant3,4 therefore patient selection is critical. • • • In a recent retrospective study in France examining PNH patients:1 – 54% had graft versus host disease (GVHD) In another study examining PNH patients (n=23)2 – 50% chronic GVHD; 42% acute GVHD Allogeneic BMT recommended for PNH patients with life-threatening cytopenias or possibly the patient with disabling hemolysis, cytopenias, or thrombosis not controlled with existing therapy5 1. De Latour PF et al. Abstract #316. EBMT 2009; 2. Santarone S et al. Hematogica. 2009; 3. Bieri S et al. BMT. 2008; 4. Fraser CJ et al. Blood. 2006; 5. Brodsky RA. Blood. 2009 113: 6522-6527 33 33 SOLIRIS® (eculizumab) SOLIRIS® is a Complement Inhibitor Indicated for the Treatment of Patients With PNH to Reduce Hemolysis SOLIRIS® is the First and Only Approved Therapy for PNH SOLIRIS® (eculizumab) [package insert]. Alexion Pharmaceuticals; 2009. 34 SOLIRIS® (eculizumab) Humanized First in Class Anti - C5 Antibody Human Framework Regions • No mutations • Germline Hinge Complementarity Determining Regions (murine origin) CH2 Rother R et al. Nat Biotech 2007;25:1256 CH3 Human IgG2 Heavy Chain Constant Region 1 and Hinge (Eliminates Fc receptor binding) Human IgG4 Heavy Chain Constant Regions 2 and 3 (Eliminates complement activation) 35 35 SOLIRIS® Blocks Terminal Complement SOLIRIS® Terminal Proximal Complement Cascade C3 C3a • Terminal complement - C5a and C5b-9 activity blocked C3b C5 C5b • SOLIRIS® binds with high affinity to C5 C5a C5b-9 Cause of Hemolysis in PNH • Proximal functions of complement remain intact • Weak anaphylatoxin • Immune complex clearance • Microbial opsonization Figueroa JE, Densen P. Clin Microbiol Rev. 1991;4(3):359-395. Walport MJ. N Engl J Med. 2001;344(14):1058-66. SOLIRIS® (eculizumab) [package insert]. Alexion Pharmaceuticals; 2009. Rother RP et al. Nature Biotech. 2007;25(11):1256-64. 36 36 SOLIRIS® PNH Clinical Studies Pilot Study – NEJM. 2004 N = 11 Primary endpoint: reduction of hemolysis TRIUMPH – NEJM. 2006 Pivotal Phase III, Double-Blind, Placebo-Controlled Trial, N = 87 Long-Term Extension Trial Hillmen Blood. 2007 Evaluated long-term safety, efficacy and effect on thrombosis; Placebo patients switched to SOLIRIS® N = 187 SHEPHERD – Blood. 2008 Broader patient population, including those receiving minimal transfusions or with thrombocytopenia, N = 97 37 37 Dosing Schedule Pretreatmen t 2 weeks before induction • • • • Induction Phase Week → 1 2 3 Maintenance Phase 4 5 6 7 8 9 and every 2 weeks thereaft er Neisseria SOLIRI S® meningitidi dose, 600patients 600 600 600 a900 X 900 Xvaccination 900 In clinical trials all received meningococcal s mg → ® should vaccination SOLIRIS be administered via IV infusion over 35 minutes every 7 days during induction and every 14 days during maintenance SOLIRIS® dose adjustment to every 12 days may be necessary for some patients to maintain LDH reduction Concomitant medications allowed: – Steroids, immunosuppressant drugs, anti-clotting agents and hematinics1 SOLIRIS® (eculizumab) [package insert]. Alexion Pharmaceuticals; 2009. 1. Hillmen P et al. N Engl J Med. 2004;350(6):552-9. 38 38 86% Reduction in LDH: Lactate Dehydrogenase (U/L) TRIUMPH and SHEPHERD 3000 TRIUMPH – Placebo/Extension TRIUMPH – SOLIRIS®/Extension 2500 SHEPHERD – SOLIRIS® 2000 1500 100% response after the first dose 1000 500 0 0 4 8 12 16 20 24 28 32 36 40 44 48 52 Time, Weeks TRIUMPH placebo patients switched to SOLIRIS® after week 26. All TRIUMPH patients entered the long-term extension study. P<0.001 at all measured time points. Hillmen P et al. Blood. 2007;110(12):4123-8. 39 39 73% Reduction in Mean Units Transfused Across all Subgroups: TRIUMPH Median Units Transfused 18 16 14 Patients not on SOLIRIS® (n=44) SOLIRIS® (n=43) 12 10 8 6 4 * * 2 * * 0 (n=87) (n=30) (n=35) (n=22) Overall 4-14 15-25 >25 Pre-treatment Transfusion Strata◘ • 51% of SOLIRIS patients achieved transfusion independence vs 0% of patients not on SOLIRIS1 • Patients with concomitant bone marrow dysfunction may continue to require minimal transfusions *P<0.001. ◘Transfusion data obtained during 12 months before treatment; values were normalized for a 6-month period 1. Hillmen P et al. N Engl J Med. 2006;355;1233-1243. 2. Schubert J. Br. J Haematol. 2008;142(2):263-72. 40 40 Median Units Packed RBCs SHEPHERD: SOLIRIS® Reduced Transfusions Regardless of Historical Transfusion Requirements 40 33.5 35 1 Year Pre-Treatment 30 1 Year Post-Treatment 25 20 17 15 10 * 8 * § 7.5 † ‡ 0 0 (n = 97) (n = 21) (n = 47) (n = 15) (n = 14) Overall < 4 Units 4 - 14 Units 15 - 25 Units > 25 Units 5 0 0 8 *P < 0.001; †P = 0.422; ‡P = 0.002; §P = 0.008. Brodsky, et al. Blood 2008; 111 (4): 1840-1847. 2 4 Transfusion Requirements 12 Months Prior to Treatment 41 Patients Report Rapid and Sustained Improvement Across Broad Range of Measures Large Impact 1 0.8 Moderate Impact 0.6 0.4 Small Impact EORTC Functioning *P<0.05. ◘P<0.001. Brodsky R et al. Blood. 2006;108(11): Abstract 3770. Data on file. Alexion Pharmaceuticals. Diarrhea Nausea Constipation Insomnia* Pain* Dyspnea◘ Cognitive* Role◘ Physical◘ Global Health◘ 0 EORTC Fatigue◘ 0.2 FACIT-Fatigue◘ Standard Effect Size (SES) 1.2 EORTC Symptoms 42 42 TRIUMPH Demonstrated that Improvement in Fatigue Occurred Independent of Hemoglobin Response FACIT-Fatigue Score ≥3 or more points denotes a clinically significant improvement 11.5 Hemoglobin, g/dL 8 P<0.001 6 11.0 4 10.5 2 Hgb Level 10.0 0 9.5 -2 9.0 -4 FACIT-Fatigue Score Change from Baseline FACIT-Fatigue Score 12.0 -6 8.5 0 2 4 6 8 10 12 14 16 Time, Weeks 18 20 22 24 26 SOLIRIS® (n=43) Patients not on SOLIRIS® (n=44) SOLIRIS® Hgb • In SHEPHERD, 78% patients reported a significant improvement in fatigue1 FACIT = Functional Assessment of Chronic Illness Therapy Adapted from: Hillmen P et al. NEJM. 2006;355:1233-43. Brodsky R et al. Blood Rev. 2008; 22: 65-74. Hill A et al. Haematologica. 2008; 93 (Suppl 1): 359. Abstract 0904. 1. Brodsky R et al. Blood. 2008;111:1840-1847. 43 43 Thrombotic Events (#) 92% Reduction in Thrombotic Events 45 40 35 30 25 20 15 10 5 0 39 N=195 P=0.0001 3 Pre-SOLIRIS® Treatment SOLIRIS® Treatment • 63% of patients received concomitant anticoagulants1 • The effect of anticoagulant withdrawal was not studied2 • Events observed in both venous and arterial sites3 PI: There were fewer thrombotic events with SOLIRIS® treatment than during the same period of time prior to treatment. 1.Brodsky R et al. Blood. 2008;111(4):1840-47. 2.SOLIRIS® (eculizumab) [package insert]. Alexion Pharmaceuticals; 2009. 3.Hillmen P, et al. Blood. 2007;110:4123-4128. 44 44 Sites and Types of Pre-Treatment Thrombotic Events Venous Thrombosis Deep Vein Thrombosis -Lower extremity -Other* Mesenteric/Splenic Vein Thrombosis Hepatic/Portal Vein Thrombosis Pulmonary Embolus Cerebral/Internal Jugular Thrombosis Superficial Vein Thrombosis Arterial Thrombosis Cerebrovascular Accident/Transient Ischemic Attack Myocardial Infarction/Unstable Angina Total Events 41 23 18 23 21 8 7 5 % of Total 33.1% 18.5% 14.5% 18.5% 16.9% 6.5% 5.6% 4.0% 17 2 124 13.7% 1.6% 100% *Includes inferior vena cava, bilateral lower extremity, pelvic, ureter, axillary, subclavian and brachiocephalic veins. Hillmen, et al. Blood 2007; 110: 4123-4128 45 Long-Term Extension Results: *P<0.001 ◘P=0.002 * * * Study Year Patient (n) 187/149 173 ◘ * 171 171 68 21 10 10 patients who participated in the pilot study demonstrated sustained reduction in LDH out past 5 years – Those patients were followed for up to 54 months showing a sustainable 86% Reduction in LDH Past 4 ½ Years. Socié G et al. Blood. 2007;110(11): Abstract 3672. SOLIRIS ® (eculizumab) [package insert]. Alexion Pharmaceuticals; 2009. 46 Summary of Clinical Efficacy In clinical trials, SOLIRIS® significantly reduced hemolysis1 • 86% sustained reduction in hemolysis as measured by LDH2 • Fewer thrombotic events were observed with SOLIRIS in clinical trials1,3 – The majority of patients (63%) received concomitant • anticoagulant therapy1 – The effect of anticoagulant withdrawal during SOLIRIS treatment has not been studied1 78% clinically meaningful improvement in fatigue • 73% reduction in need for transfusions across all patient populations2 1. SOLIRIS® (eculizumab) [package insert]. Alexion Pharmaceuticals; 2009. 2. Hillmen P et al. N Engl J Med. 2006;355:1233-43. 3. Hillmen P et al. Blood. 2007;110(12):4123-8. 4. Socie G et al. Blood. 2007;110(11)::Abstract 3672. 47 47 Soliris: Warning • SOLIRIS® increases the risk of • meningococcal infections. Meningococcal infection may become rapidly life-threatening or fatal if not recognized and treated early. – Vaccinate patients with a meningococcal vaccine at least 2 weeks prior to receiving the first dose of SOLIRIS® – Revaccinate according to current medical guidelines for vaccine use – Monitor patients for early signs of meningococcal infections, evaluate immediately if infection is suspected, and treat with antibiotics if necessary SOLIRIS® (eculizumab) [package insert]. Alexion Pharmaceuticals; 2009. 48 48 Soliris: Serious Adverse Events Clinical Trial Experience • Meningococcal infections are the most important • • • adverse events that may be experienced by patients receiving SOLIRIS® In clinical studies, 2 out of 196 patients developed serious meningococcal infections while receiving treatment with SOLIRIS – Both patients had been vaccinated In clinical studies among non-PNH patients, meningococcal meningitis occurred in one patient, who was unvaccinated In post-marketing experience, cases of serious or fatal meningococcal infections have been reported SOLIRIS® (eculizumab) [package insert]. Alexion Pharmaceuticals; 2009. 49 49 Safety: Contraindications • SOLIRIS® is contraindicated for patients with unresolved serious Neisseria meningitidis infection or who are not currently vaccinated against Neisseria meningitidis SOLIRIS® (eculizumab) [package insert]. Alexion Pharmaceuticals; 2009. 50 50 Safety: Warnings and Precautions • The effect of withdrawal of anticoagulant • therapy during SOLIRIS® treatment has not been established. Therefore, treatment with SOLIRIS® should not alter anticoagulant management Patients who discontinue SOLIRIS® must be monitored closely for signs of serious hemolysis – If serious hemolysis occurs after SOLIRIS discontinuation, consider the following procedures/treatments: blood transfusion (packed RBCs), or exchange transfusion if the PNH RBCs are >50% of the total RBCs by flow cytometry; anticoagulation; corticosteroids; or reinstitution of SOLIRIS – In clinical trials, 16 of 196 PNH patients discontinued SOLIRIS® treatment; no serious hemolysis was observed SOLIRIS® (eculizumab) [package insert]. Alexion Pharmaceuticals; 2009. 51 51 Adverse Reactions Reported in ≥ 5% of SOLIRIS® Treated Patients in TRIUMPH Patients, n (%) Reaction SOLIRIS® (n = 43) Placebo (n = 44) Headache 19 (44) 12 (27) Nasopharyngitis 10 (23) 8 (18) Back pain 8 (19) 4 (9) Nausea 7 (16) 5 (11) Fatigue 5 (12) 1 (2) Cough 5 (12) 4 (9) Herpes simplex virus infections 3 (7) 0 Sinusitis 3 (7) 0 Respiratory tract infection 3 (7) 1 (2) Constipation 3 (7) 2 (5) Myalgia 3 (7) 1 (2) Pain in extremity 3 (7) 1 (2) 2 (5) 1 (2) SOLIRIS® (eculizumab) [package insert]. Alexion Pharmaceuticals; 2009. Influenza-like illness 52 52 Eculizumab-Pro’s and Con’s • Pro’s – Very effective at reducing – – – – hemolysis Well tolerated Improvements in QOL, reduction in transfusions Reduction in burden of disease Probable reduction in clots • Con’s – $$$$!! – Infection risk: – – – – meningococcal meningitis Burden of treatment Plan for lifetime therapy Does not improve other blood counts Is not curative 55 Important questions yet to be answered: • • • • • Many questions need to be answered: – Why do PNH cells evolve the way they do? – Who is at a higher risk of clotting? – What is a clinically meaningful clone size? What are the long term side effects of soliris, and does it reverse end organ damage? Does Soliris prolong survival in PNH patients? Who is the ideal candidate for transplantation? Can we identify a “kind” transplant regimen with less toxicity and long term side effects? 56 Shared Experiences Around the World Enhancing the Understanding of PNH Outcomes 57 US and International Participation in The PNH Registry: • As of August 2009: 7 Countries Enrolling – US – Argentina – Denmark – Netherlands – Belgium – Australia – France – Others are coming on board 58 Registry: Eligibility • • • All patients with any PNH clone regardless of treatment Patient willing to complete a questionnaire at Baseline and every six months thereafter Willing and able to give written informed consent 59 Conclusions • • • • PNH is a disease of chronic hemolysis with a heterogeneous clinical presentation. Stem cell transplant is the only curative option but it has significant morbidity associated with the procedure Soliris is effective at reducing transfusion frequency, risk of thrombosis & improves QoL, but is not curative. Advancing our understanding of disease biology is critical for improving outcomes. 60